natgillin/translations-raw huggingface dataset:
Administration af ISENTRESS sammen med aluminium- og magnesiumholdige antacida medførte nedsat plasmakoncentration af raltegravir.
Co-administration of ISENTRESS with aluminium and magnesium antacids resulted in reduced raltegravir plasma levels.
Administration af ISENTRESS sammen med aluminium- og/eller magnesiumholdige antacida frarådes derfor.
Therefore, co-administration of ISENTRESS with aluminium and/or magnesium containing antacids is not recommended.
Administration af ISENTRESS sammen med aluminium- og/eller magnesiumholdige antacida frarådes.
with aluminium and/or magnesium containing antacids is not recommended.
Administration af ISENTRESS sammen med lægemidler, der er kendt som potente UGT1A1- hæmmere (f.eks. atazanavir), kan øge raltegravirs plasmakoncentrationer.
Co-administration of ISENTRESS with medicinal products that are known to be potent UGT1A1 inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir.
Administration af ivacaftor sammen med rifampicin, en potent CYP3A-inducer, nedsatte eksponeringen for ivacaftor (AUC) med 89 % og nedsatte M1 i mindre grad end ivacaftor.
Co-administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased M1 to a lesser extent than ivacaftor.
Administration af jodholdigt kontraststof
Administration of iodinated contrast agent
administration af Kaletra og
The use of vardenafil with Kaletra
administration af Kaletra og disse
administration of Kaletra and
Administration af ketoconazol (en CYP3A4-hæmmer) 400 mg én gang daglig sammen med dabrafenib 75 mg to gange daglig resulterede i en stigning på 71 % i dabrafenib-AUC og en stigning på 33 % i dabrafenib-Cmax i forhold til dabrafenib 75 mg to gange daglig administreret alene.
Administration of ketoconazole (a CYP3A4 inhibitor) 400 mg once daily, with dabrafenib 75 mg twice daily, resulted in a 71% increase in dabrafenib AUC and a 33% increase in dabrafenib Cmax relative to administration of dabrafenib 75 mg twice daily alone.
Administration af knuste Xarelto 15 mg eller 20 mg filmovertrukne tabletter skal straks efterfølges af enteral ernæring (se pkt.
After the administration of crushed Xarelto15 mg or 20 mg film-coated tablets, the dose should then be immediately followed by enteral feeding (see section 5.2).
Administration af knuste Xarelto 15 mg eller 20 mg filmovertrukne tabletter, skal straks efterfølges af enteral ernæring (se pkt.
After the administration of crushed Xarelto15 mg or 20 mg film-coated tablets, the dose should then be immediately followed by enteral feeding (see section 5.2).
Administration af levende eller levende svækkede vacciner til patienter, som er immunkompromitterede på grund af kemoterapeutika, herunder ONIVYDE, kan medføre alvorlige og dødelige infektioner, og vaccination med levende vacciner bør derfor undgås.
Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic medicinal products including ONIVYDE may result in serious or fatal infections; therefore vaccination with a live vaccine should be avoided.
Administration af levende vacciner til spædbørn inden for 16 uger efter moderens sidste Benepali-dosis må derfor almindeligvis frarådes.
Administration of live vaccines to infants for 16 weeks after the mother’s last dose of Benepali is generally not recommended.
Administration af levende vacciner til spædbørn inden for 16 uger efter moderens sidste Enbrel-dosis anbefales generelt ikke.
Administration of live vaccines to infants for 16 weeks after the mother’s last dose of Enbrel is generally not recommended.
Administration af levende vacciner til spædbørn, som har været eksponeret for adalimumab i utero, anbefales ikke i 5 måneder efter moderens sidste adalimumab-injektion under graviditeten.
Administration of live vaccines to infants exposed to adalimumab in utero is not recommended for 5 months following the mother’s last adalimumab injection during pregnancy.
Administration af levende vacciner til spædbørn, som har været eksponeret for adalimumab in utero, anbefales ikke i 5 måneder efter moderens sidste adalimumab-injektion under graviditeten.
Administration of live vaccines to infants exposed to adalimumab in utero is not recommended for 5 months following the mother’s last adalimumab injection during pregnancy.
Administration af lokalanæstetikum før injektion af Xiapex i en Dupuytrens streng anbefales ikke, da det kan påvirke den korrekte placering af injektionen.
Administration of a local anaesthetic medicinal product prior to injection of Xiapex into a Dupuytren’s cord is not recommended, as it may interfere with proper placement of the injection.
Administration af lumacaftor/ivacaftor
Concomitant use of lumacaftor/ivacaftor
Administration af lumacaftor/ivacaftor
No dose adjustment of lumacaftor/ivacaftor
administration af maraviroc
co-administration (based
Administration af Marixino til patienter med svært nedsat leverfunktion frarådes.
Administration of Marixino is not recommended in patients with severe hepatic impairment.
Administration af Memantin Accord til patienter med svært nedsat leverfunktion kan ikke anbefales.
Administration of Memantine Accord is not recommended in patients with severe hepatic impairment.
Administration af Memantine LEK til patienter med svært nedsat leverfunktion kan ikke anbefalese.
Administration of Memantine LEK is not recommended in patients with severe hepatic impairment.
Administration af Memantine Merz til patienter med svært nedsat leverfunktion kan ikke anbefales.
Administration of Memantine Merz is not recommended in patients with severe hepatic impairment.
Administration af Memantine Merz til patienter med svært nedsat leverfunktion kan ikke anbefalese.
Administration of Memantine Merz in patients with severe hepatic impairment is not recommended.
Administration af Menveo en måned efter Tdap medførte en statistisk markant lavere serogruppe W135-responsrate.
The administration of Menveo one month after Tdap resulted in statistically significantly lower serogroup W135 seroresponses.
Administration af nintedanib var forbundet med forhøjede leverenzymer (ALAT, ASAT, alkalisk fosfatase (ALKP), gamma-glutamyltransferase (GGT)) med en potentielt øget risiko hos kvindelige patienter.
Administration of nintedanib was associated with elevations of liver enzymes (ALT, AST, alkaline phosphatase (ALKP), gamma-glutamyl-transferase (GGT)) with a potentially higher risk for female patients.
Administration af nintedanib var forbundet med forhøjelse af leverenzymer (ALAT, ASAT, ALKP, gammaglutamyltransferase) eller bilirubin, med en potentielt øget risiko for kvindelige patienter.
Administration of nintedanib was associated with an elevation of liver enzymes (ALT, AST, ALKP, gamma-glutamyltransferase) or bilirubin, with a potentially higher risk for female patients.
Administration af nintedanib var også forbundet med forhøjet bilirubin.
Administration of nintedanib was also associated with elevations of bilirubin.
administration af norethisteron
administration of
administration af OATP-
of OATP substrates/inhibitors.
Administration af ONIVYDE sammen med andre CYP3A4-hæmmere (f.eks. grapefrugtjuice, clarithromycin, indinavir, itraconazol, lopinavir, nefazodon, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazol) kan derfor øge den systemiske eksponering for ONIVYDE.
Therefore, co-administration of ONIVYDE with other inhibitors of CYP3A4 (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) may increase systemic exposure of ONIVYDE.
Administration af ONIVYDE sammen med CYP3A4-induktorer kan derfor reducere den systemiske eksponering for ONIVYDE.
Therefore, co-administration of ONIVYDE with inducers of CYP3A4 may reduce systemic exposure of ONIVYDE.
Administration af Orkambi kan nedsætte den systemiske eksponering for lægemidler, som er substrater for CYP3A, og derved reducere deres terapeutiske virkning.
Administration of Orkambi may decrease systemic exposure of medicinal products which are substrates of CYP3A, thereby decreasing their therapeutic effect.
Administration af Palladia skal ophøre og passende behandling iværksættes, hvis der er mistanke om gastrointestinal ulceration, uanset om det skyldes Palladia eller degranulering af mastcelletumordegranuleringer.
If gastrointestinal ulceration is suspected, whether or not due to Palladia or to mast cell tumour degranulation, stop the administration of Palladia and treat appropriately.
Administration af Parareg sammen med mad giver en stigning på ca.
Administration of Parareg with food results in an approximate 50
Administration af pazopanib sammen med måltider med et højt eller lavt fedtindhold resulterer i en 2- folds stigning i AUC og Cmax.
Administration of pazopanib with a high fat or low fat meal results in an approximately 2-fold increase in AUC and Cmax.
Administration af PREZISTA 800 mg en gang dagligt med lavdosis ritonavir til behandlingsnaive unge i alderen 12 til 17 år med en legemsvægt på mindst 40 kg fører til eksponering for darunavir inden for det terapeutiske område som påvist hos voksne, der får samme dosisregime.
Administration of PREZISTA 800 mg once daily with low dose ritonavir in treatment-naïve adolescents 12 to 17 years weighing at least 40 kg leads to darunavir exposures within the therapeutic range as established in adults receiving the same dosing regimen.
administration af PREZISTA med
co-administration of PREZISTA
administration af PREZISTA og lavdosis
when co-administered with PREZISTA
Administration af radioaktive lægemidler medfører en risiko for andre personer (herunder gravide kvinder blandt sundhedspersonalet) for ekstern stråling eller kontamination fra spild af urin, opkast osv.
The administration of radiopharmaceuticals creates risks for other persons (including pregnant healthcare professionals) from external radiation or contamination from spill of urine, vomiting etc.
Administration af radioaktive lægemidler udgør en risiko for andre personer (herunder gravide medlemmer af det sundhedsfaglige personale) fra ekstern bestråling eller kontaminering fra spildt urin, opkast osv.
The administration of radiopharmaceuticals creates risks for other persons (including pregnant healthcare professionals) from external radiation or contamination from spill of urine, vomiting etc.
Administration af raltegravir efter et måltid med højt fedtindhold øgede AUC og Cmax ca.
Administration of raltegravir following a high-fat meal increased AUC and Cmax by approximately 2-fold and increased C12 hr by
Administration af regorafenib (160 mg i 14 dage) før administration af en enkeltdosis rosuvastatin (5 mg), et BCRP-substrat, gav en stigning i den gennemsnitlige eksponering (AUC) for rosuvastatin på 3,8 gange og en stigning i Cmax på 4,6 gange.
Administration of regorafenib (160 mg for 14 days) prior to administration of a single dose of rosuvastatin (5 mg), a BCRP substrate, resulted in a 3.8-fold increase in mean exposure (AUC) of rosuvastatin and a 4.6-fold increase in Cmax.
administration af REYATAZ/
Co-administration of
Administration af Rotarix til børn, som har en kendt eller mistænkt immundefektsygdom, skal baseres på en nøje overvejelse af potentielle fordele og risici.
Administration of Rotarix to infants who have known or suspected immunodeficiency should be based on careful consideration of potential benefits and risks.
Administration af Senshio samtidig med stærke/moderate CYP3A4-hæmmere skal derfor undgås hos patienter med en kendt eller mistænkt dårlig CYP2C9-metabolisering baseret på genotypebestemmelse eller tidligere anamnese/erfaring med andre CYP2C9-substrater.
Therefore, co-administration of Senshio with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known, or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.
Administration af Soliris kan medføre infusionsreaktioner eller kan være immunogent og udløse allergiske reaktioner eller hypersensibilitet (herunder anafylaksi).
Administration of Soliris may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis), though immune system disorders within
Administration af sunitinib sammen med potente CYP3A4-hæmmere (f.eks. ritonavir, itraconazol, erythromycin, clarithromycin, grapefrugtjuice) kan øge sunitinibkoncentrationen.
Administration of sunitinib with potent CYP3A4 inhibitors (e.g. ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice) may increase sunitinib concentrations.
Administration af sunitinib sammen med potente CYP3A4-induktorer (f.eks. dexamethason, phenytoin, carbamazepin, rifampin, phenobarbital eller naturlægemidler som indeholder perikon/Hypericum perforatum) kan nedsætte koncentrationen af sunitinib.
Administration of sunitinib with potent CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John’s Wort/Hypericum perforatum) may decrease sunitinib concentrations.
Administration af SUTENT bør afbrydes og/eller dosis bør reduceres hos patienter unden kliniske tegn på CHF, men med en uddrivningsfraktion på <50%->20% under baseline.
The administration of sunitinib should be interrupted and/or the dose reduced in patients without clinical evidence of CHF but with an ejection fraction <50% and >20% below baseline.
Administration af TMZ i kombination med andre myelosuppresserende lægemidler kan øge risikoen for myelosuppresion.
Use of TMZ in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.
Administration af to samtidige Xiapex-injektioner i Dupuytrens strenge på samme hånd blev evalueret i det kliniske studie AUX-CC-867, et historisk kontrolleret åbent multicenterstudie hos 715 voksne personer (1450 Xiapex-injektioner) med Dupuytrens kontraktur.
The administration of two concurrent Xiapex injections into Dupuytren’s cords in the same hand was evaluated in clinical study AUX-CC-867, a historically-controlled, open-label multi-centre trial in 715 adult subjects (1450 Xiapex injections) with Dupuytren’s contracture.
Administration af trastuzumabemtansin er veltolereret hos rotter og aber i doser op til henholdsvis 20 og 10 mg/kg, svarende til 2.040 g DM1/m2 i begge arter, hvilket nogenlunde svarer til den kliniske dosis af trastuzumabemtansin til patienter.
Administration of trastuzumab emtansine was well tolerated in rats and monkeys at doses up to 20 and 10 mg/kg, respectively, corresponding to 2040 g DM1/m2 in both species, which is approximately equivalent to the clinical dose of trastuzumab emtansine in patients.
administration af trazodon og
co-administration of trazodone
Administration af Tresiba en gang dagligt viste den samme reduktion i HbA1c i uge 52 og større reduktion i FPG fra baseline versus komparatoren insulin detemir, der blev doseret en eller to gange dagligt.
Tresiba dosed once daily showed similar reduction in HbA1c at week 52 and greater reduction in FPG from baseline versus the comparator insulin detemir dosed once or twice daily.
Administration af tyggetabletten sammen med et måltid med højt fedtindhold påvirker ikke raltegravirs farmakokinetik i en klinisk betydningsfuld grad, og tyggetabletten kan administreres uden hensyntagen til mad.
Administration of the chewable tablet with a high fat meal does not affect raltegravir pharmacokinetics to a clinically meaningful degree and the chewable tablet can be administered without regard to food.
Administration af tyggetabletten sammen med et måltid med højt fedtindhold påvirker ikke raltegravirs farmakokinetik i klinisk betydningsfuld grad, og tyggetabletten kan administreres uden hensyn til mad.
Administration of the chewable tablet with a high fat meal does not affect raltegravir pharmacokinetics to a clinically meaningful degree and the chewable tablet can be administered without regard to food.
Administration af vandetanib sammen med stoffer, der vides at forlænge QTc-interval på EKG, er kontraindiceret eller frarådes (se pkt.
The administration of vandetanib with substances known to prolong the ECG QTc interval is contraindicated or not recommended (see sections 4.3 and 4.5).
Administration af vandetanib sammen med stoffer, der vides at forlænge QTc-interval på EKG’et, er kontraindiceret eller frarådes (se pkt.
The administration of vandetanib with substances known to prolong the ECG QTc interval is contraindicated or not recommended (see section 4.3 and 4.5).
Administration af vedolizumab til drægtige cynomolgus aber under det meste af drægtigheden resulterede ikke i nogen tegn på virkninger på teratogenicitet, prænatal eller postnatal udvikling hos unger op til 6 måneder.
Administration of vedolizumab to pregnant cynomolgus monkeys during most of gestation resulted in no evidence of effects on teratogenicity, prenatal or postnatal development in infants up to 6 months of age.
Administration af veterinærlægemidlet ved subkutan injektion hos kvæg og intramuskulært injektion hos svin er veltolereret, og kun en lille forbigående hævelse på injektionsstedet efter subkutan administration var observeret hos kvæg behandlet i kliniske studier.
Administration of the product by the subcutaneous route in cattle and the intramuscular route in pigs is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in cattle treated in clinical studies
Administration af veterinærlægemidlet ved subkutan injektion hos kvæg og intramuskulært injektion hos svin er veltolereret, og kun en lille forbigående hævelse på injektionsstedet efter subkutan administration var observeret hos kvæg behandlet i kliniske studier.
Administration of the veterinary medicinal product by the subcutaneous route in cattle and the intramuscular route in pigs is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in cattle treated in clinical studies
Administration af Viramune i højere doser end anbefalet kan forøge frekvensen og alvorligheden af hudreaktioner, såsom Stevens-Johnsons syndrom og toksisk epidermal nekrolyse.
Nevirapine administration above the recommended dose might increase the frequency and seriousness of skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Administration af Viread 33 mg/g granulat med henblik på at give en reduceret daglig dosis tenofovirdisoproxilfumarat anbefales til voksne patienter med kreatininclearance < 50 ml/min, herunder hos hæmodialyse-patienter.
Administration of Viread 33 mg/g granules to provide a reduced daily dose of tenofovir disoproxil fumarate is recommended for adult patients with creatinine clearance < 50 ml/min, including haemodialysis patients.
Administration af VIZAMYL og udførelse af proceduren
Administration of VIZAMYL and conduct of the procedure
Administration af VWF gør det muligt at korrigere for hæmostatiske afvigelser hos patienter, der lider af VWF-mangel (von Willebrands sygdom) på to måder:
Administration of VWF allows correction of the haemostatic abnormalities exhibited by patients who suffer from VWF deficiency (VWD) at two levels:
Administration af Xofigo og sådan udføres proceduren
Administration of Xofigo and conduct of the procedure
Administration af ZALTRAP/FOLFIRI bør udsættes, indtil neutrofiltallet er 1,5 x 109/l eller trombocyttallet er
Administration of ZALTRAP/FOLFIRI should be delayed until neutrophil count is 1.5 x 109/L or platelet count is
Administration af én dosis på 1 mg digoxin sammen med liraglutid resulterede i en reduktion af AUC for digoxin på 16 %, og Cmax blev reduceret med 31 %.
A single dose administration of digoxin 1 mg with liraglutide resulted in a reduction of digoxin AUC by 16%; Cmax decreased by 31%.
Administration af én dosis på 20 mg lisinopril sammen med liraglutid resulterede i en reduktion af AUC for lisinopril på 15 %, og Cmax blev reduceret med 27 %.
A single dose administration of lisinopril 20 mg with liraglutide resulted in a reduction of lisinopril AUC by 15%; Cmax decreased by 27%.
administration anbefales hyppig
blood concentrations, changes in renal
Administration begyndte med en dosis på 11,25 og eskalerede til 15, 30, 40, 52 og 70 mg/ m2/dag som intravenøs infusion i 5 dage hver 2. – 6. uge afhængigt af toksicitet og respons.
Dosing commenced at 11.25 with escalation to 15, 30, 40, 52 and 70 mg/m2/day by intravenous infusion for 5 days every 2 to 6 weeks depending on toxicity and response.
Administration i begge øjne
Bilateral treatment
Administration i kombination med en aromatasehæmmer
Administration in combination with an aromatase inhibitor
Administration Intravenøs brug.
Method of administration Intravenous use.
administration med
when administered with
Administration med anden medicin
Administration with other medicinal products
administration med boostet
co-administered with boosted
administration med efavirenz.
co-administration with efavirenz.
Administration med et meget fedtrigt måltid (917 kcal, 60% kalorier fra fedt) var forbundet med et gennemsnitlig fald på henholdsvis 32 og 49% i ritonavirs AUCinf og Cmax, forbundet med enfastende tilstand.
Administration with a high fat meal (917 kcal, 60% calories from fat) was associated with a mean decrease of 32 and 49% in ritonavir AUCinf and Cmax respectively, relative to fasting conditions.
Administration med et måltid med højt fedt- og kalorieindhold forsinker levodopa- absorptionen med op til 2 timer.
Administration with a high-fat, high-calorie meal delays levodopa absorption by up to 2 hours.
Administration med FlexPen.
Administration with FlexPen
Administration med injektionssprøjte
Administration with a syringe
Administration med insulindispenseringssystem
Administration with an insulin delivery system
administration med Kaletra
with Kaletra
administration med lopinavir/ritonavir.
co-administering with
administration med lopinavir/ritonavir.
lopinavir/ritonavir.
administration med PREZISTA
co-administered with PREZISTA
Administration med sprøjte
Administration with a syringe
administration med tenofovir
administered with tenofovir, it is
Administration med væske
Administering with liquid
Administration of orale paliperidon-depottabletter ved steady-state (12 mg en gang dagligt) sammen med divalproexnatrium-depottabletter (500 mg til 2000 mg en gang dagligt) havde ingen indvirkning på steady state-farmakokinetikken for valproat.
Co-administration of oral paliperidone prolonged release tablets at steady-state (12 mg once daily) with divalproex sodium prolonged release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.
Administration Okulær anvendelse.
Method of administration For ocular use.
Administration om aftenen: Behandling med Cetrotide bør påbegyndes på den 5. dag af ovariestimulationen (cirka 96 til 108 timer efter påbegyndt ovariestimulation) med urinekstraherede eller rekombinante gonadotropiner og bør fortsættes gennem hele gonadotropin-behandlingsperioden indtil aftenen før fremkaldelse af ægløsning.
Administration in the evening: Treatment with Cetrotide should commence on day 5 of ovarian stimulation (approximately 96 to 108 hours after start of ovarian stimulation) with urinary or recombinant gonadotropins and is to be continued throughout the gonadotropin treatment period until the evening prior to the day of ovulation induction.
Administration om morgenen: Behandling med Cetrotide bør påbegyndes på den 5. eller 6. dag af ovariestimulationen (cirka 96 til 120 timer efter påbegyndt ovariestimulation) med urinekstraherede eller rekombinante gonadotropiner og bør fortsættes gennem hele gonadotropin-behandlingsperioden til og med dagen for fremkaldelse af ægløsning.
Administration in the morning: Treatment with Cetrotide should commence on day 5 or 6 of ovarian stimulation (approximately 96 to 120 hours after start of ovarian stimulation) with urinary or recombinant gonadotropins and is to be continued throughout the gonadotropin treatment period including the day of ovulation induction.
Administration Oral anvendelse
Method of administration For oral use
Administration Oral anvendelse.
Method of administration For oral use.